|
Innovest Global, Inc. $IVST is a diversified Public Holding company that is already a ten-bagger this year with much more on the way based on fundamentals AND technicals!
IVST massive breaking news:
IVST is pleased to announce that the acquisition of Authority National Supply (ANS) is closed. ANS was our sixth transaction to date, and has generated $22.8 million in sales through the first three quarters of 2018. IVST now has approximately 55 employees and $34 million in annual run-rate revenue.
Innovest Global Signed LOI to Acquire Midwest Curtainwalls, a $12 Million Revenue and Profitable Business. Midwest is a company that will add to our Construction and Building Materials efforts. They generate $10-$12 million in annual revenue from specialty commercial construction contracts, with projections of $2.4 million in profit from current contract
Innovest Global, Inc. (OTC Markets: IVST) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Our primary growth strategy is to acquire niche, high-growth businesses that are capable of generating significant annual revenue. Planned subsidiaries operate across telehealth, biotech, building materials, commercial energy, business-to-business distribution, national call center and auto sales.
Based out of Cleveland, Ohio, IVST is easily one of the better fundamental companies trading on the OTC marketplace. Innovest Global, Inc. is already up 10-fold in 2018, after starting off 2018 around $0.02 before shooting to an all-time high of $0.50 in March 2018. IVST continues to hold onto the nice gains thus far holding strong in the .25-.30 range ready for the next leg back into the .50 range it tested earlier this year. Based upon the company’s strong fundamental AND technical picture, Innovest Global, Inc. could easily retake its all-time high by the end of 2018.
What a stock structure IVST has folks! The company has an amazing unchanged free-trading float of 11,796,710 common shares with no convertible debts, no warrants or options outstanding, and employs 45.
Onto the meat and potatoes:
IVST owns 20% of StemVax Therapeutics which is the first company in its Biotech Division.
StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. Lead by world-renowned neuroscientist, Dr. Dwain Morris-Irvin, the Biotech & Health Sciences Division is currently focused on commercializing StemVax’s cancer vaccination therapy technology. The cancer vaccination therapy technology was just recently awarded a U.S. patent! We seek to make a difference in patient’s lives bringing new beginnings to the market by developing novel therapeutics.
IVST’s management team has been extremely busy with its pending mega-acquisition of a building materials company, which produces $30 million in annual revenues! Once the building materials company is acquired, it will serve as Innovest Global’s third division. The initial discussions began back in March 2018, followed by formal negotiations in April 2018. In June, Innovest management formally proposed the acquisition pitch to the target company’s board of directors. Upon conclusion of the presentation, both parties had signed and executed a Letter of Intent (LOI) document. In late August 2018, it was announced that both parties have effectively reached an agreement on the acquisition transaction structure and long form documents. We expect this to “formally” close at any moment.
IVST has the vision and model of Berkshire-Hathaway, we look forward to its evolution!
|
